Lipoid Nephrosis (MCNS)

Categories: Blood diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Lipoid Nephrosis

MalaCards integrated aliases for Lipoid Nephrosis:

Name: Lipoid Nephrosis 12 15 17 71
Minimal Change Glomerulonephritis 12 6
Minimal Change Disease 12 52
Nephrotic Syndrome with Lesion of Minimal Change Glomerulonephritis 12
Nephrotic Syndrome with Lesion of Minimal Change Nephrotic Syndrome 12
Idiopathic Minimal Change Nephrotic Syndrome 52
Glomerulonephritis, Minimal Change 71
Nephrotic Syndrome, Minimal Change 71
Minimal Change Nephrotic Syndrome 52
Nephrotic Syndrome Minimal Change 54
Minimal Change Glomerulopathy 52
Nephrosis, Lipoid 43
Mcns 52


External Ids:

Disease Ontology 12 DOID:10966
MeSH 43 D009402
NCIt 49 C34844
SNOMED-CT 67 44785005
ICD10 32 N04
UMLS 71 C0027721 C1704320 C1704321

Summaries for Lipoid Nephrosis

NIH Rare Diseases : 52 Minimal change disease is a kidney disease in which there is damage to the filtering units of the kidney (glomeruli). It is the most common cause of nephrotic syndrome in children. Nephrotic syndrome is comprised of a group of symptoms including protein in the urine (proteinuria ), low protein levels in the blood, high cholesterol and triglycerides, an increased risk for blood clots, and swelling. Other features of this disease include weight gain and a foamy appearance of the urine. The cause of minimal change disease is unknown, but it may occur following an allergic reaction or infection. Treatment may involve the use of steroids.

MalaCards based summary : Lipoid Nephrosis, also known as minimal change glomerulonephritis, is related to c1q nephropathy and focal segmental glomerulosclerosis. An important gene associated with Lipoid Nephrosis is NPHS1 (NPHS1 Adhesion Molecule, Nephrin), and among its related pathways/superpathways are NF-kappaB Signaling and IL4-mediated signaling events. The drugs Tacrolimus and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include kidney, monocytes and testes, and related phenotypes are immune system and renal/urinary system

Wikipedia : 74 Minimal change disease (also known as MCD, minimal change glomerulopathy, and nil disease, among others)... more...

Related Diseases for Lipoid Nephrosis

Diseases related to Lipoid Nephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 526)
# Related Disease Score Top Affiliating Genes
1 c1q nephropathy 32.8 CD79A CD40LG
2 focal segmental glomerulosclerosis 31.7 SYNPO PODXL NPHS2 NPHS1 ITGB1 CD2AP
3 nephrotic syndrome 31.4 SYNPO NPHS2 NPHS1 CD2AP ALB ACTN4
4 idiopathic nephrotic syndrome 31.3 NPHS2 ALB
5 glomerulonephritis 31.1 NPHS2 NPHS1 CD79A CD40LG CCL2 ALB
6 mesangial proliferative glomerulonephritis 30.9 CD79A CD40LG CCL2
7 membranoproliferative glomerulonephritis 30.8 NPHS1 CD79A ALB
8 chronic graft versus host disease 30.7 IL10 CD79A ALB
9 acute kidney tubular necrosis 30.7 NAGLU CD40LG ALB
10 food allergy 30.7 IL4R IL13 IL10 ALB
11 parotitis 30.6 CD79A CD40LG ALB
12 end stage renal disease 30.6 NPHS2 NPHS1 CD2AP ALB ACTN4
13 iga nephropathy 1 30.6 SERPINB7 NPHS2 NPHS1 CD79A
14 nephrotic syndrome, type 2 30.5 NPHS2 NPHS1 ACTN4
15 bacterial infectious disease 30.5 SERPINA3 IL10 CD40LG CCL2
16 dermatitis, atopic 30.5 SERPINA3 IL4R IL13 IL10 CCL2
17 hypoparathyroidism, sensorineural deafness, and renal disease 30.5 NPHS2 NPHS1 ACTN4
18 bacterial meningitis 30.4 IL10 CCL2 ALB
19 glomerular disease 30.4 NPHS2 NPHS1 CD79A CD2AP ALB
20 nephrotic syndrome, type 10 30.4 PODXL NPHS2 NPHS1
21 autoimmune pancreatitis 30.4 IL10 CD40LG ALB
22 purpura 30.4 IL10 CD79A CD40LG
23 nephrosclerosis 30.4 SYNPO NPHS2 NPHS1 CCL2
24 goodpasture syndrome 30.4 PLA2R1 NPHS1 CD40LG ALB
25 tetanus 30.4 IL13 IL10 CD79A CD40LG ALB
26 hyper ige syndrome 30.4 IL4R IL13 IL10
27 microvascular complications of diabetes 3 30.3 SERPINB7 NPHS1 NAGLU ALB
28 calciphylaxis 30.3 CD79A CD40LG ALB
29 guillain-barre syndrome 30.3 CD79A CD40LG ALB
30 ige responsiveness, atopic 30.2 IL4R IL13 IL10
31 myeloma, multiple 30.2 SERPINA3 IL10 CD79A CD40LG CCL2 ALB
32 nephrotic syndrome, type 1 30.2 NPHS2 NPHS1 CD2AP ACTN4
33 membranous nephropathy 30.2 PODXL PLA2R1 NPHS2 NPHS1 CD79A CD2AP
34 urticaria 30.1 IL13 IL10 CD40LG
35 peripheral nervous system disease 30.0 SERPINA3 IL10 CD40LG CCL2 ALB
36 sarcoidosis 1 30.0 SERPINA3 IL13 CD40LG CCL2
37 rhinitis 30.0 IL4R IL13 IL10 ALB
38 behcet syndrome 30.0 IL13 IL10 CD40LG CCL2 ALB
39 exanthem 30.0 IL10 CD40LG ALB
40 brucellosis 30.0 IL13 IL10 CD40LG
41 immune deficiency disease 30.0 SERPINA3 IL13 IL10 CD79A CD40LG CCL2
42 iga glomerulonephritis 30.0 SYNPO SERPINB7 PLA2R1 NPHS2 NPHS1 CD79A
43 cryoglobulinemia 29.9 IL10 CD79A CD40LG
44 cellulitis 29.9 SERPINA3 IL10 CD40LG
45 wilms tumor 1 29.9 SYNPO SERPINA3 PODXL NPHS2 NPHS1
46 vasculitis 29.9 SERPINA3 IL10 CD79A CD40LG CCL2
47 viral hepatitis 29.8 SERPINA3 IL10 CD40LG ALB
48 malaria 29.8 SERPINA3 IL4R IL13 IL10 CD40LG CCL2
49 otitis media 29.8 IL13 IL10 CD79A CD40LG CCL2 ALB
50 diabetes mellitus, type i 29.8 NAGLU IL13 IL10 CD79A CD40LG CCL2

Graphical network of the top 20 diseases related to Lipoid Nephrosis:

Diseases related to Lipoid Nephrosis

Symptoms & Phenotypes for Lipoid Nephrosis

MGI Mouse Phenotypes related to Lipoid Nephrosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 ACTN4 ALB CCL2 CD2AP CD40LG CD79A
2 renal/urinary system MP:0005367 9.32 ACTN4 ALB CD2AP CD40LG CD79A ITGB1

Drugs & Therapeutics for Lipoid Nephrosis

Drugs for Lipoid Nephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Vaccines Phase 4
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
13 Cyclosporins Phase 4
14 Calcineurin Inhibitors Phase 4
15 Antitubercular Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Adrenocorticotropic Hormone Phase 4
20 Melanocyte-Stimulating Hormones Phase 4
21 beta-Endorphin Phase 4
22 Hormones Phase 4
23 Methylprednisolone Acetate Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Hormone Antagonists Phase 4
26 glucocorticoids Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Trace Elements Phase 4
29 Micronutrients Phase 4
30 Vitamins Phase 4
31 Nutrients Phase 4
32 Calciferol Phase 4
33 Hydroxycholecalciferols Phase 4
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
Mycophenolic acid Approved Phase 3 24280-93-1 446541
rituximab Approved Phase 3 174722-31-7 10201696
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40 Psychotropic Drugs Phase 2, Phase 3
41 Anticonvulsants Phase 2, Phase 3
42 Neurotransmitter Agents Phase 2, Phase 3
43 Immunosuppressive Agents Phase 3
44 Immunologic Factors Phase 3
45 Antirheumatic Agents Phase 3
46 Antineoplastic Agents, Immunological Phase 3
47 Immunoglobulins Phase 3
48 Antibodies Phase 3
49 Gastrointestinal Agents Phase 3
50 Antiemetics Phase 3

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome Unknown status NCT02649413 Phase 4 Prednisone
2 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
3 Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
4 Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome Completed NCT01185197 Phase 4 Myfortic plus low-dose steroid;Prednisolone
5 Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease Completed NCT00982072 Phase 4 tacrolimus;prednisolone
6 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
7 Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
8 A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome Unknown status NCT02896270 Phase 2, Phase 3 Valproic Acid
9 A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
10 Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
11 A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
12 A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study) Completed NCT00981838 Phase 3 Rituximab
13 Cyclophosphamide Versus Mycophenolate Mofetil for Children With Steroid-dependent Idiopathic Nephrotic Syndrome : a Multicenter Randomized Controlled Trial Completed NCT01092962 Phase 3 Cyclophosphamide;Mycophenolate mofetil
14 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Completed NCT02438982 Phase 3 Tacrolimus;Rituximab
15 Pulse Dexamethasone Over 48 Weeks for Podocyte Disease Completed NCT00065611 Phase 3 Oral dexamethasone
16 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone Recruiting NCT03298698 Phase 3 Rituximab;Prednisone
17 A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) Completed NCT02592798 Phase 2 Abatacept
18 Retinoids for Podocyte Disease Completed NCT00098020 Phase 2 Isotretinoin
19 The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts Completed NCT01475331 Phase 2 Ethanol;Normal Saline;Chemotherapy
20 Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Recruiting NCT04009668 Phase 2 adalimumab
21 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Active, not recruiting NCT03970577 Phase 2 Rituximab;Prednisone
22 The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease) Active, not recruiting NCT02966717 Phase 2 Rituximab;conventional therapy;Mesenchymal stem cells
23 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Not yet recruiting NCT04387448 Phase 2 GFB-887;Placebo
24 A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia Withdrawn NCT03965624 Phase 2 Ninlaro
25 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
26 Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE Unknown status NCT03592030
27 A Study on the Diagnosis of Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and Gastroesophageal Reflux Disease Using Linked Color Imaging Unknown status NCT03068572
28 Different Histopathological Patterns in Patients With HCV Nephropathy Unknown status NCT03476031
29 Physiopathogenic Mechanisms Involved in Diabetic Nephropathy, Looking for Prevention and Treatment Solutions Unknown status NCT02237352
30 Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease Completed NCT01835639
31 The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy Completed NCT01451710 Prednisone or Prednisolone
32 Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome Completed NCT00577525
33 Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome Completed NCT01609426
34 Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study Completed NCT01113385 D-Galactose
35 Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics Completed NCT02869893 Secretin
36 Kidney Disease Biomarkers Completed NCT00255398
37 Diagnostic Efficacy of Narrow Band Imaging (NBI) in Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00886197
38 Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease Recruiting NCT04369183
39 A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) Recruiting NCT04235621
40 The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) Recruiting NCT03949972
41 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
42 Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network Recruiting NCT01209000
43 The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project Recruiting NCT03786263
44 A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood. Recruiting NCT04207580
45 Effect of Daily Transcutaneous Auricular Vagus Nerve (taVNS) Stimulation on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome Recruiting NCT04169776
46 INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics) Recruiting NCT01605266
47 Early Detection of Pancreatic Cystic Neoplasms Recruiting NCT02110498
48 Molecular and Genetic Analysis of Inherited Kidney Dysfunction Active, not recruiting NCT02194582
49 Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East Active, not recruiting NCT03326037
50 Global Kidney Patient Trials Network Not yet recruiting NCT04389827

Search NIH Clinical Center for Lipoid Nephrosis

Cochrane evidence based reviews: nephrosis, lipoid

Genetic Tests for Lipoid Nephrosis

Anatomical Context for Lipoid Nephrosis

MalaCards organs/tissues related to Lipoid Nephrosis:

Kidney, Monocytes, Testes, Pancreas, T Cells, Bone, Thyroid

Publications for Lipoid Nephrosis

Articles related to Lipoid Nephrosis:

(show top 50) (show all 671)
# Title Authors PMID Year
A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. 54 61
18985619 2009
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 61 54
19562271 2009
Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. 61 54
9346389 1997
Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. 61 54
8247178 1993
Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis. 61
31473631 2019
[Minimal change disease and focal segmental glomerulosclerosis]. 61
30887070 2019
Diagnosis and management of nephrotic syndrome. 61
29020719 2017
50 Years Ago in The Journal of Pediatrics: Effect of Cyclophosphamide on Lipoid Nephrosis in the Human and on Aminonucleoside Nephrosis in the Rat. 61
27017462 2016
The Treatment of IgA Nephropathy. 61
27536661 2015
[Minimal-change glomerulonephritis in chronic lymphocytic leukemia: A clinical case]. 61
26978424 2015
Role of Angptl4 in vascular permeability and inflammation. 61
24173241 2014
Patterns of childhood nephrotic syndrome in Aljouf region, Saudi Arabia. 61
24029283 2013
Interstitial nephritis with moderate-to-heavy proteinuria: an unusual combination. 61
22382248 2012
[Hodgkin's disease revealed by a nephrotic syndrome: a case report with literature review]. 61
22123569 2011
Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. 61
20886250 2011
[Clinical-pathological characteristics of IgM nephropathy in 34 children]. 61
20497638 2010
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. 61
19343274 2010
Nephrotic syndrome and Guillan-Barré Syndrome: a rare association in child. 61
20061709 2010
Genetic effect of the NPHS2 gene variants on proteinuria in minimal change disease and immunoglobulin A nephropathy. 54
20025681 2009
Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. 61
19520469 2009
[A case of sternoclavicular joint tuberculosis with renal failure due to rifampicin]. 61
19764465 2009
Historical development of the renal histopathology services in Malaysia. 54
19694308 2009
Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs. 61
18927121 2009
Mesangioproliferative glomerulonephritis: an important glomerulonephritis in nephrotic syndrome of young adult. 61
18723953 2008
[Choroidal effusion after uncomplicated cataract surgery]. 61
18516782 2008
Endothelial microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy. 61
18799061 2008
[Nephrotic syndrome: don't forget to search for hypothyroidism]. 61
18191306 2008
Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. 54
18032547 2008
[Graves disease, hypothyroidism, and minimal-change glomerulonephritis]. 61
18454723 2008
Quiz page. Minimal change glomerulonephritis associated with secondary syphilis. 61
17687805 2007
[Nephrotic syndrome associated with minimal-change glomerulonephritis and chronic lymphocytic leukaemia]. 61
18336109 2007
Expression profile of nephrin, podocin, and CD2AP in Chinese children with MCNS and IgA nephropathy. 54
16941146 2006
Role of podocyte slit diaphragm as a filtration barrier. 54
16889564 2006
Idiopathic reversible renal failure in a young woman with minimal change glomerulonephritis. 61
16903627 2006
Minimal change glomerulonephritis in chronic lymphocytic leukemia: pathophysiological and therapeutic aspects. 61
16601371 2006
Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. 54
16759810 2006
Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome. 54
16739878 2006
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 54
16285662 2005
Nephrotic syndrome preceding Hodgkin's lymphoma by 13 months. 61
16175948 2005
Thin basement membrane nephropathy associated with other glomerular diseases. 61
15880329 2005
Nephrotic syndrome after stem cell transplantation. 61
15659148 2005
No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. 61
15730048 2005
Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome. 54
15687724 2005
[History of nephrotic syndrome]. 61
15500117 2004
Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). 54
15086927 2004
Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. 61
14758527 2004
[Pathogenesis of immune glomerulonephritis]. 54
15008213 2003
[Lipoid nephrosis in childhood]. 61
15008217 2003
[Histological classification of chronic glomerular diseases]. 61
15008214 2003
[Minimal Change Glomerulonephritis]. 61
14566462 2003

Variations for Lipoid Nephrosis

ClinVar genetic disease variations for Lipoid Nephrosis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LMX1B NM_001174147.2(LMX1B):c.737G>C (p.Arg246Pro)SNV Likely pathogenic 812901 9:129455598-129455598 9:126693319-126693319

Expression for Lipoid Nephrosis

Search GEO for disease gene expression data for Lipoid Nephrosis.

Pathways for Lipoid Nephrosis

GO Terms for Lipoid Nephrosis

Cellular components related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 SERPINA3 PLA2R1 IL4R IL13 IL10 CD40LG
2 extracellular exosome GO:0070062 9.81 SERPINA3 PODXL NPHS2 NPHS1 NAGLU ITGB1
3 extracellular space GO:0005615 9.65 SERPINB7 SERPINA3 PODXL IL4R IL13 IL10
4 membrane raft GO:0045121 9.62 PODXL NPHS2 ITGB1 CD79A
5 platelet alpha granule lumen GO:0031093 9.43 SERPINA3 ALB ACTN4
6 slit diaphragm GO:0036057 8.8 PODXL NPHS2 NPHS1

Biological processes related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.83 IL4R IL13 IL10 CD40LG CCL2
2 cytokine-mediated signaling pathway GO:0019221 9.55 ITGB1 IL4R IL13 IL10 CCL2
3 positive regulation of mast cell degranulation GO:0043306 9.46 IL4R IL13
4 B cell proliferation GO:0042100 9.43 IL10 CD79A CD40LG
5 glomerular visceral epithelial cell development GO:0072015 9.4 PODXL NPHS1
6 positive regulation of immunoglobulin production GO:0002639 9.37 IL4R IL13
7 CD40 signaling pathway GO:0023035 9.32 ITGB1 CD40LG
8 positive regulation of macrophage activation GO:0043032 9.13 IL4R IL13 IL10
9 B cell differentiation GO:0030183 8.92 ITGB1 IL10 CD79A CD40LG

Molecular functions related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL13 IL10 CD40LG CCL2

Sources for Lipoid Nephrosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....